Login to Your Account

Ambrx Lands Another Pharma in Potential $300M Astellas Deal

By Marie Powers
Staff Writer

Friday, April 5, 2013
Privately held Ambrx Inc. gained another partner for one of its signature technologies, attracting Tokyo-based Astellas Pharma Inc. to an oncology-focused discovery and development collaboration in antibody drug conjugates (ADCs).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription